of personal identifiers to ensure anonymity. Subsequent to the beta
trial period, the opportunity to contribute data to the database was
extendedtoallOSDuserswhoconsentedtothedatasafetystatement.
Notably, data collection remains ongoing to the present day.
For the beta trial, individuals with partial-onset epilepsy, partic-
ularly those susceptible to absence or complex focal seizures, were
intentionallyexcludedduringtheinitialphaseofdatacollection.This
decision was predicated on the absence of tonic, atonic, myoclonic,
or clonic movements typically associated with generalised epilepsy.
Consequently,amongtheparticipantswhosigneduptothebetatrial,